Prevention of Invasive Meningococcal Disease in the United States: Current State of the Art

Corwin A Robertson**, Philipp Oster¹, David R Johnson¹, Albert Reinhardt¹, David P Greenberg¹ and Michael D Decker¹

¹Sanofi Pasteur, Swiftwater, Pennsylvania, USA
²Sanofi Pasteur, Lyon, France

Abstract

*Neisseria meningitidis* causes potentially fatal and often debilitating invasive meningococcal disease (IMD). IMD remains a serious health problem for healthcare providers and public health officials despite approximately 80% of US IMD being vaccine-preventable. In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended routine immunization of adolescents aged 11-12 years and, in 2007, this recommendation was expanded to include all adolescents aged 11-18 years. Adolescent disease burden has since declined. For new vaccination strategies to improve beyond standard of care, they must account for current epidemiologic trends. This review articles the current epidemiology of IMD in the United States, highlighting known risk factors. Prior ACIP recommendations (and their rationale) since the approval of the first quadrivalent conjugate meningococcal vaccine in 2005 are summarized. The scientific and logistical issues associated with extending those recommendations to include infants and other at-risk groups are also discussed.

Keywords: Meningococcal disease; Immunization; Conjugate vaccine; Adolescents; Infants, epidemiology; United states; Advisory committee on immunization practices

Abbreviations: ABCs: Active Bacterial Core surveillance; ACIP: Advisory Committee on Immunization Practices; FDA: US Food and Drug Administration; HIV: Human Immunodeficiency Virus; hsBA: Serum Bactericidal Assay using Human Complement; IMD: Invasive Meningococcal Disease; MCC: Meningococcal Serogroup C Conjugate Vaccine; MCV4: Quadrivalent Conjugated Meningococcal Vaccine; MPSV4: Meningococcal Quadrivalent Polyosaccharide Vaccine; OMV: Outer Membrane Vesicles; rSBA: Serum Bactericidal Assay using Baby Rabbit Complement; VE: Vaccine Effectiveness

Introduction

Invasive Meningococcal Disease (IMD) remains a vexing problem for providers, public health officials and advisory bodies, despite multiple healthcare intervention strategies. This review examines immunization strategies for IMD in light of recent US epidemiologic trends. Future vaccines and vaccination strategies are also considered.

*Neisseria meningitidis* is an aerobic gram-negative bacterium responsible for IMD, there are at least a dozen phenotypically distinct *N. meningitidis* serogroups. These serogroups are differentiated by the biochemical and structural characteristics of the bacterium’s polysaccharide capsule. The meningococcal polysaccharide capsule plays a major role in determining the characteristics of the bacterium. Five serogroups-A, B, C, W (formerly W-135) and Y-are responsible for the majority of invasive disease [1]. In the United States, serogroups B, C and Y are major causes of IMD, with each responsible for approximately one third of cases [2]. The proportion of IMD cases caused by each serogroup varies over time and by age group. For children aged 1 year and younger, more than 50% of IMD cases are caused by serogroup B, for which there currently is no vaccine licensed in the United States [3]. By contrast, 75% of IMD cases among patients aged 11 years and older are vaccine-preventable, caused by serogroups C, W, or Y [3].

The most common clinical manifestations of IMD are meningitis, septicemia and pneumonia [4]. Although less common than streptococcal and pneumococcal disease [5-8], IMD is associated with high morbidity and mortality, and approximately 11-19% of individuals with the condition develop permanent physical or neurologic sequelae [9]. In one US study examining data collected during 1998-2007, IMD was associated with an overall case-fatality rate of 10.1% [10]. Among college students aged 17-4 years in Pennsylvania, a case-fatality rate of 19% was observed [11]. With meningococcemia, the risk is even greater, with up to 40% of cases ending in death [4]. Of particular concern is the rapid course of the disease, with the possibility of death occurring in as few as 24 hours [11].

The epidemiology and incidence of IMD can vary dramatically, both over time and geographically [4,12]. Since 2000, the incidence of IMD has decreased in the United States and is currently at an historic low. Yet, some patient populations remain at elevated risk for disease. These at-risk populations include infants and very young children, adolescents, the elderly [13] and individuals with compromised immune systems or certain genetic polymorphisms [14]. Other factors (e.g., environmental and socioeconomic) are also associated with an increased risk of disease and include residing in a crowded setting, such as a dormitory, and smoking or exposure to second-hand smoke [15].

Vaccines against selected meningococcal serogroups are available and can prevent a substantial percentage of IMD cases. Furthermore, these vaccines can be used in a wide range of patient populations. In the United States, three quadrivalent vaccines developed against serogroups A, C, W and Y are currently available [4]. The first quadrivalent vaccine was meningococcal quardivalent polysaccharide

*Corresponding author: Corwin A Robertson, Sanofi Pasteur, Swiftwater, Pennsylvania, USA, Tel: +1-570-957-0968; E-mail: corwin.robertson@sanofipasteur.com*

Received September 23, 2013; Accepted November 15, 2013; Published November 20, 2013


Copyright: © 2013 Robertson CA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
vaccine (MPSV4; Menomune®, Sanofi Pasteur), which demonstrates good vaccine effectiveness (VE) and an acceptable tolerability profile in most groups examined [16]. However, polysaccharide vaccines are poorly immunogenic in young children and do not induce immunologic memory [16,17]. Since the introduction of MPSV4, two quadrivalent conjugated meningococcal vaccines (MCV4) have been licensed in the United States [18,19]. Conjugated vaccines are effective across many age groups, produce a robust and anamnestic immune response and are associated with a reduction in IMD [17-23]. In addition, the impact on oropharyngeal carriage and transmission has been demonstrated for serogroups A, C, and Y [16,24,25] and is assumed for serogroup W. Meanwhile, the development of a vaccine against serogroup B has been challenging; the poor immunogenicity of the polysaccharide capsule is a consequence of its similarity to components of fetal and neural tissues [26,27]. Serogroup B vaccines composed of PorA-specific Outer Membrane Vesicles (OMV) have been used with success to control clonal outbreaks in Cuba and New Zealand [28,29]. Because such vaccines are directed against antigens specific to local serogroup B strains (serosubtypes), these vaccines would not be effective in continental countries, which have more diverse circulating serogroup B strains [28]. Currently, a serogroup B vaccine, combining the New Zealand OMV and several recombinant antigens, with potentially broader strain coverage, has been licensed in Europe but not in the United States.

US Epidemiology

Overview

In the United States, N. meningitidis is responsible for both sporadic and epidemic disease [13,30]. The annual incidence of meningococcal disease has varied from 0.5-1.5 cases per 100,000 since World War II [31]. In recent years, the overall rate of IMD in the general US population declined from 0.92 cases per 100,000 in 1998 [32,33] to 0.15 per 100,000 in 2010—a historic low [34].

In 2011, the most recent year for which data are available from the Active Bacterial Core surveillance (ABCs) program—an active surveillance system for invasive disease caused by selected bacterial pathogens—a total of 620 cases of IMD were estimated nationally, with 100 estimated fatalities (16%) [7]. This represents a ≥ 3-fold reduction from approximately a decade earlier, when national case and death estimates were 2200 and 300, respectively [35]. Although the precise reasons for the decline in IMD are unknown, changes in environmental, behavioral, microbial and host factors are suspected [33]. Immunization practices may have had an impact, specifically in pre-adolescents and adolescents for whom universal vaccination is recommended [36]. Among persons aged 11-19 years, the incidence of IMD caused by serogroups C, W and Y decreased by approximately 50% in 2008 and 2009 compared with the rate observed during 1993-2005 [32].

ABCs data also reveal that the distribution of serogroups in the United States changes over time. In 2011, serogroup Y accounted for 36% of the 75 IMD cases detected by the system [7] (Figure 1). This is in contrast to the period 1989-1991 when serogroup Y caused only 2% of detected IMD cases [37] (Figure 1). Despite a decrease in relative prevalence from 45% in 1989-1991 to 25% in 2011, serogroup C still remains a major cause of vaccine-preventable IMD [7,37]. These changes in serogroup distribution emerged over a period of approximately 2 decades. In the pre-World War II era, serogroup A was the cause of very large US epidemics [38], but in recent decades, few or no serogroup A cases have been reported [7]. Though the proportion of W disease has remained relatively low in the United States [7,34,39,40], serogroup W has been responsible for recent outbreaks (including in the Western hemisphere) [41]. This observation suggests that serogroup W has the potential to become an increasing threat in the United States. Given the varying epidemiology of IMD, as well as increasing global travel, a prudent vaccination strategy from both the personal and the public health viewpoint is to provide broad rather than narrow serogroup coverage.

As noted, IMD incidence rates vary by age. The rates of IMD are highest in infants and very young children, decline throughout childhood, rise again in adolescence, decline during most of adulthood, but then begin rising again in the sixth and later decades of life (indeed, rates among those aged 65 years and older approach those seen in adolescents, likely due to declining immune competence) [3]. In young children, the higher rate of IMD may reflect less developed innate and specific immunity against N. meningitidis [42,43]. Meningococcal carriage prevalence also varies with age and, interestingly, the prevalence is highest in adolescence and lowest in young children [44]. The increase in carriage prevalence from childhood to adolescence suggests that the disease peak in adolescents may be related to increased exposure in this population [44]. Consistent with this observation, there is an increased incidence of IMD in college students (typically aged 18-22 years), who tend to reside within dormitories, a known risk factor for both N. meningitidis carriage [45] and clinical disease [46-48]. This increased risk of IMD among dormitory residents was observed in the United States as early as the 1990s [47,49] and has also been observed in other countries. A significantly greater incidence of IMD was reported among UK university students versus age-matched nonstudents [48]. In 2011, a higher rate of vaccine-preventable IMD was observed in young adults aged 18-22 years (0.15 per 100,000) compared with adolescents aged 11-17 years (0.03 per 100,000) [7]. The lower rate in the adolescents may also reflect changes in the 2005 Advisory Committee on Immunization Practices (ACIP) vaccination recommendations, as a comparison of the same age groups prior to the availability of MCV4 revealed that the incidence rate from these two cohorts was more similar (18-22 years: 0.26 per 100,000 vs. 11-17 years: 0.18 per 100,000) [50].

Prior to routine vaccination of recruits, military personnel, who commonly reside in congregate housing, also experienced a higher rate of IMD than the general population [51]. Likely risk factors include prolonged close contact with other soldiers, exposure to peers carrying serogroups not native to the soldier’s home and deployment.
as carriers before departing the United States; however, 1.3% of study participants had evidence of serogroup W carriage after returning to the United States [66]. Travel was also implicated in another outbreak of serogroup W disease in southeastern Florida from 2008-2009. Common exposures, social settings or other connections among patients could not be identified, but the dominant clonal complex observed was identical to the dominant type observed in a recent Argentina and Brazil outbreak, suggesting importation from South America [41]. Most recently, a nationwide increase in serogroup W disease was reported in Chile, with 83 confirmed cases and 22 deaths occurring from January 2012 through June 2013 [67]. These incidents highlight the need for continued surveillance as serogroups uncommon in the United States can easily be imported.

Although outbreaks—once detected—can be managed with reactive vaccination, this strategy is not ideal, as substantial disease can occur before mobilizing immunization efforts [47]. Chemoprophylaxis of close contacts is routine, but drug administration within 24 hours of meningococcal exposure is advised for optimum protection [4]. The issue of chemoprophylaxis is confounded by antibiotic-resistant N. meningitidis strains; fluoroquinolone-resistant N. meningitidis has been detected in Minnesota and North Dakota [68,69].

Meningococcal vaccines in the United States and acip recommendations

Beginning in 1969, meningococcal polysaccharide monovalent vaccines for serogroups A and C were introduced in the US based upon efficacy studies in human volunteers [70]. These vaccines were found to be effective and well tolerated in older children and adults. In children aged 18 months and younger, the monovalent meningococcal serogroup C polysaccharide vaccine was poorly immunogenic and, similar to monovalent A vaccine, provided relatively short-term protection. The persistence of immunity from both vaccines was 3-5 years. In 1981, the first quadrivalent polysaccharide meningococcal vaccine was approved for use in persons aged ≥ 2 years [71]. The response to the vaccine is consistent with that to a T-cell–independent antigen: an age-dependent response, with poor immunity in children aged <2 years. MPSV4 consists of a lyophilized component of group-specific polysaccharide antigens from N. meningitidis serogroups A, C, Y and W. MPSV4 is approved for use in persons aged ≥ 2 years [72]. The response to the vaccine is consistent with that to a T-cell–independent antigen: an age-dependent response, with poor immunity in children aged <2 years. MPSV4 use in US military personnel during 1983-1998 successfully prevented IMD, with a 40% reduction from the crude disease rate for the period 1979-1982, while a similar decline in disease incidence has not been observed in older adults [53], although a 6-fold decrease occurred in the late 1980s among military recruits [54].

### Table 1: Reported outbreaks of invasive meningococcal disease in the US, 2003-2013.

<table>
<thead>
<tr>
<th>Location</th>
<th>Cohort affected</th>
<th>Cases, n</th>
<th>Case-fatality rate, % (n)</th>
<th>Serogroup</th>
<th>Year</th>
<th>Vaccination used as a control measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crook County, OR [58]</td>
<td>Aged &lt; 25 y</td>
<td>6</td>
<td>0 (0)</td>
<td>C</td>
<td>2011–2012</td>
<td>Yes</td>
</tr>
<tr>
<td>Larimer County, CO [59-61]</td>
<td>College students and adult hockey team</td>
<td>9</td>
<td>56 (5)</td>
<td>C</td>
<td>2010</td>
<td>Yes</td>
</tr>
<tr>
<td>Rogers County, OK [62]</td>
<td>Elementary school students (aged 6–8 y) plus one high school student</td>
<td>5</td>
<td>40 (2)</td>
<td>C</td>
<td>2010</td>
<td>Yes</td>
</tr>
<tr>
<td>Southeastern, FL [41]</td>
<td>Aged 1–84 y</td>
<td>14</td>
<td>29 (4)</td>
<td>W</td>
<td>2006–2009</td>
<td>No†</td>
</tr>
<tr>
<td>Chicago, IL [64]</td>
<td>Men who have sex with men</td>
<td>6</td>
<td>50 (3)</td>
<td>C</td>
<td>2003</td>
<td>Yes</td>
</tr>
</tbody>
</table>

* A 23rd man from outside NYC who spent significant time in the NYC boroughs also became ill but later recovered
† Broad age range and varied demographics made it difficult to identify whom to vaccinate
As noted, college students have both high rates of *N. meningitidis* carriage [45] and clinical disease [46-48]. To prevent IMD in high-risk college students, ACIP recommended in 2000 that 1) healthcare providers should inform students and their parents of the increased risk of IMD and of the potential benefits of MPSV4 vaccination, 2) that colleges and universities should implement IMD educational programs, and 3) that MPSV4 should be readily available to students [72].

To enhance IMD prevention, public health officials called on industry to develop conjugate vaccines against *N. meningitidis*. Conjugation alters the immune response by inducing a T-cell–dependent response as opposed to the T-cell–independent (i.e., B-cell only) immune response. The former is more robust and longer lasting and leads to immune memory. Furthermore, conjugated vaccines can be used in children aged < 2 years and may reduce *N. meningitidis* carriage [73]. In 2005, a meningococcal (groups A, C, Y and W) polysaccharide diphtheria toxoid conjugate vaccine (Menactra®, Sanofi Pasteur; MenACWY-D) was licensed in the United States as a liquid formulation in a single vial [18]. The approval of MenACWY-D was based on studies comparing immunogenicity of a single MenACWY-D dose to a single MPSV4 dose, as assessed by postvaccination levels of complement-dependent serum bactericidal antibody (SBA).* A substantial increase in SBA was observed in individuals vaccinated with MenACWY-D [17,74-77].

In 2005, ACIP recommended routinely immunizing 11-12 year olds with one dose of Men ACWY-D during their yearly health care visit, and for adolescents older than 12 years, vaccination was recommended to occur before high school entry. Routine vaccination for those aged 11-55 years was also recommended if they were college freshman living in dormitories, microbiologists working with *N. meningitidis*, military recruits, travelers to IMD hyperendemic or epidemic areas or individuals with terminal complement deficiencies or asplenia [3] (Figure 2). Due to initial vaccine supply limitations, a catch-up program was not recommended [78].

In June 2007, ACIP revised its recommendation to include routine vaccination of all 11-18 year olds with one dose of Men ACWY-D at the earliest opportunity [78]. ACIP continued to recommend that 11-12 year olds be routinely vaccinated [78] (Figure 2). Partly as a result of these recommendations, vaccination coverage increased substantially among adolescents. In 2008, 41.8% of 13-17 year olds had received at least one dose of meningococcal vaccine; by 2012, the percentage had increased to 74.0% [84,85]. While MenACWY-D coverage did vary substantially by state following its introduction in 2005 [84], as previously mentioned, by 2008-2009, the proportion of IMD attributable to serogroups C, W and Y had decreased approximately 50% in persons aged 11–19 years compared with the rate observed during 1993-2005 [32]. Although these are encouraging trends, efforts to increase population vaccine coverage need to continue [21].

The VE of MenACWY-D was estimated by analyzing cases reported to both the ABCs and MeningNet, a passive surveillance system. Within 3-4 years, MenACWY-D VE was calculated to be 80-85% [22], despite the absence of a catch-up vaccination program and limited vaccine coverage among adolescents. This early VE estimate is similar to the efficacy measured for MPSV4 [22]. For comparison, a UK vaccine coverage campaign with meningococcal serogroup C conjugate vaccine (MCC) targeted both infants and those aged <18 years and achieved vaccine coverage rates exceeding 85% in most cohorts. The VE of MCC used in this campaign was estimated to be 96% within 1 year of vaccination [22,23].

In December 2007, the MenACWY-D indication was broadened to include children aged 2-10 years [20] based on results from a

---

**Figure 2:** History of ACIP recommendations on the prevention of invasive meningococcal disease with meningococcal conjugate vaccine [3,20,36,79-83].

*Complement is a necessary reagent for antibody-mediated killing of meningococci in serum bactericidal assays. Use of complement from either baboon or human sources is considered acceptable by the US Food and Drug Administration as a basis of licensure of meningococcal vaccines among adolescents and adults, whereas human complement is preferred for studies among infants and young children. Of note, human complement is difficult to obtain and has highly variable activity from batch to batch [74-76]. In contrast, baboon rabbit is more easily obtained and has been shown to produce consistent and reproducible results [76,77]. For US licensure purposes, serum bactericidal assay (SBA) titer levels presumed to provide protection against meningococcal disease are ≥ 1:128 for SBA using baboon rabbit complement (rSBA) and ≥ 1:8 for SBA using human complement (hSBA).
modified double-blinded, randomized, controlled study that found MenACWY-D was more immunogenic than MPSV4 [86]. However, ACIP advised against the routine immunization of all 2-10 year olds, instead recommending vaccination only for those at an increased risk of IMD [20,82] (Figure 2). This recommendation reflects current disease epidemiology (disease incidence in 2-10 year olds is lower than in infants and adolescents) and the notion that immunologic responses elicited in 2 year olds are unlikely to protect into adolescence—the next high-risk age period [82]. The 2007 recommendation also stated that vaccination with Men ACWY-D was preferable to MPSV4 and that for children aged 2-10 years previously vaccinated with a polysaccharide vaccine, a 3-year follow-up Men ACWY-D vaccination was recommended.

In 2010, the FDA approved a meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACYW-CRM; Menveo®, Novartis). This vaccine was the second conjugate vaccine targeting serogroups A, C, W and Y; collectively MenACWY-D and MenACWY-CRM are abbreviated as MCV4. MenACYW-CRM consists of meningococcal polysaccharides conjugated to a nontoxic mutated diphtheria toxin (CRM197) [19]. The MenACYW-CRM presentation consists of two vials: a vial containing vaccine against serogroups C, W and Y in a liquid formulation and a vial containing lyophilized vaccine against serogroup A. The vial contents are mixed before MenACYW-CRM administration [19]. Initially, MenACYW-CRM was approved for individuals aged 11–55 years, but in 2011, the approved age range was extended to children aged 2-10 years and then to children as young as 2 months of age in 2013 [19,80]. The approval of MenACYW-CRM in persons 2 years–55 years was based upon SBA responses in individuals vaccinated with either MeneCYW-CRM or MenACYW-D. Antibody responses after MenACYW-CRM vaccination were found to be noninferior to MenACYW-D vaccination for all serogroups except for serogroup A in children aged 2-10 years (the proportion with serogroup A hSBA titers ≥ 1.8 for MenACYW-CRM vs. MenACYW-D were 72% vs. 77% for 2-5 year olds and 77% vs. 83% for 6-10 year olds) [19,87]. Follow-up in adolescents 22 months postvaccination demonstrated that those immunized with MenACYW-CRM had higher hSBA titers than those who received MenACYW-D [88]. However, at 3 years postimmunization, the titer differences had waned and the proportions of adolescents with hSBA ≥ 1.8 against each of the four serogroups was similar for MenACYW-D and MenACYW-CRM [80]. The clinical relevance of initially higher antibody titers is unclear [89]. Although VE data for MenACYW-CRM are not available, the vaccine has been shown to reduce carriage of serogroups C, W, and Y combined (reduction of 36%) in English university students ≥ 2 months after vaccination [25].

Analysis of 2006-2010 data demonstrated that the VE of MenACYW-D wanes over time. Based on this finding and antibody persistence data for both MenACYW-D and MenACYW-CRM, ACIP hypothesized that approximately 50% of individuals immunized at age 11-12 years would be unprotected beyond 5 years [36] (representing the high-risk period at age 16-21 years). Although it might appear that quadrivalent polysaccharide vaccines offer a similar duration of protection [36], it must be remembered that polysaccharide vaccines neither prime nor boost, whereas readministration of conjugate vaccine produces a strong anamnestic response [17]. In 2010, ACIP continued to recommend the routine immunization of 11-12 year olds with MCV4, but added the stipulation that a booster dose be administered at age 16 years [36] (Figure 2).
fact that presently the amount of vaccine-preventable IMD at this stage of life is low. Serogroup B is responsible for the majority of IMD cases, approximately 60%, within the first year of life and it is not targeted by either MCV4 or HibMenCY-TT [3]. Meanwhile, serogroups C and Y, which are included in current vaccines, are associated with disease incidence rates of 0.3 and 0.9 per 100,000 children aged <1 year (vs. 2.8 per 100,000 for serogroup B) [3]. Similarly, in children aged 2-4 years, the incidence rates are 0.1, 0.1 and 0.3 per 100,000 population for serogroups C, Y and B, respectively [3]. Mathematical models based on 2007-2009 epidemiologic data indicated that routine infant immunization would prevent 44 cases and 2-4 deaths per year, with a correspondingly high cost per quality-adjusted life year [32].

The relatively high cost of a universal infant recommendation is not the only barrier to its implementation. Such a recommendation is unlikely to contribute to herd immunity, as infants are not the primary reservoirs of *N. meningitidis*: adolescents and young adults are [100]. In the United Kingdom, a catch-up immunization program targeted persons aged <18 years with MCC. This program was associated with a reduction in carriage rates by 66% in students aged 15-17 years [53] and a 67% reduction in the attack rate among the unvaccinated [101]. Thus, increased US adolescent coverage for both the primary and booster doses might improve herd immunity in that group, allowing for at least partial protection of those remaining unvaccinated, and could further impede bacterial transmission to infants and young children [32], thus augmenting vaccine effectiveness [101]. Lastly, the immaturity of the infant immune system requires more doses to achieve protective antibody titers than required later in life. A meta-analysis demonstrated that a single dose of an MCC administered to toddlers was as effective as a three-dose series administered during infancy [102].

Discussion

In summary, there are four vaccines licensed in the United States for the prevention of meningococcal disease. MPSV4 (Menomune®; Sanofi Pasteur, Swiftwater, PA) is a quadrivalent polysaccharide vaccine approved for use in persons aged 2 years and older [71]. MenACWY-D (Menactra®; Sanofi Pasteur, Swiftwater, PA) and MenACWY-CRM (Menveo®; Novartis Vaccines and Diagnostics, Cambridge, MA) are quadrivalent conjugate vaccines; the former is approved for use in persons aged 9 months through 55 years and the latter is approved for use in persons aged 2 months through 55 years [18,19]. Finally, HibMenCY-TT (MenHibrix®; GlaxoSmithKline, Rixensart, Belgium) is a conjugate vaccine that covers two meningococcal serogroups (C and Y) and is approved for use in children aged 6 weeks through 18 months [98]. Several considerations regarding use of these vaccines in certain age groups follow.

Based on current epidemiology and vaccine characteristics, ACIP recommends routine immunization with a conjugate vaccine for infants and children who have certain risk factors for meningococcal disease. Due to the prevalence of serogroups A and W outside the United States, ACIP recommends use of MenACWY-D for infants and toddlers aged 9 months through 23 months who will travel to areas where meningococcal disease is hyperendemic or epidemic [3]. ACIP recommendations for use of MenACWY-CRM in infants at high risk for IMD are not yet available. ACIP does not recommend use of MenACWY-D in children aged <2 years of age with anatomic or functional asplenia who have not completed their pneumococcal conjugate vaccine series [81]. This guidance was based on pneumococcal disease being more important than IMD in this population and clinical trial data that suggest MenACWY-D may interfere with immune responses to pneumococcal conjugate vaccine [81] (although results of a functional [opsonophagocytic] assay suggest otherwise) [103].

Another noteworthy consideration regarding the use of meningococcal vaccines in childhood is that HibMenCY-TT cannot be concomitantly administered with other infant combination vaccines containing Hib antigens [3].

The ACIP recommendation to immunize 11-12 year olds with MCV4, followed by a booster dose at age 16 years, reflects the increased risk of disease in this cohort [36]. Partly as a result of vaccination, disease incidence has declined, but a broader herd immunity effect has not yet been confirmed, as disease remains stable in other age cohorts. The absence of an observed herd effect might be the result of still less than optimal vaccination coverage among adolescents and the lack of a broad-based catch-up program (e.g., from young children through young adults, as employed in the United Kingdom, Netherlands, and elsewhere). Given that the highest burden of preventable IMD occurs in adolescents and young adults, prevention efforts should continue to be focused on this group [32]. Moreover, adolescents are carriers of *N. meningitidis*, and the indirect benefits of herd immunity could be realized with improved coverage.

Although conjugate vaccines are not approved for use in persons aged 56 years and older, concerns about hyporesponsiveness following repeated doses of MPSV4 prompted ACIP to recommend that persons aged ≥ 56 years previously vaccinated with a meningococcal vaccine and who remain at increased risk for IMD (e.g., microbiologists working with isolates of *N. meningitidis*, travelers and persons at risk as a result of a community outbreak) be revaccinated with MCV4 [3].

Despite advances in vaccine development, several challenges to IMD prevention in the United States remain. In infants and young children, effective prevention of IMD requires the ability to target serogroup B, since it is this serogroup that causes the greatest percentage of disease in this age group. Recently, a meningococcal group B vaccine (rDNA, component, adsorbed) (4CMenB, Bexsero®; Novartis Vaccines & Diagnostics) with the potential to offer broad coverage against a number of serogroup B strains was approved for use in the European Union. The vaccine was found to be immunogenic when given as a four-dose series beginning at age 2 months [104], although the clinical effectiveness of 4CMenB has yet to be determined.

New MCV4 vaccines for infants are also on the horizon. In the European Union but not in the United States, a new meningococcal group A, C, W and Y conjugate vaccine (MenACWY-TT, Nimenrix®; GlaxoSmithKline Biologicals) was approved for use in children aged 12 months and older [105]. A conjugate vaccine based on MenACWY-TT, known as TetraMen-T (Sanofi Pasteur), is in phase II clinical trials. Other early pipeline vaccines are also under development, including vaccines protecting against all five clinically important serogroups (i.e., A, B, C, W, and Y).

Comparing meningococcal vaccines is complicated by the fact that immunogenicity comparisons of the various meningococcal vaccines—either those that are currently available or on the horizon—cannot be done reliably on the basis of SBA titer results from disparate results. The SBA requires fresh complement, but different lots of complement—particularly human complement—can give markedly different results. The issue is further complicated by lack of standardization in study design, procedures, data collection and analysis (e.g., differences in study populations, and the use or nonuse of concomitant vaccines, as well as differences in serology laboratories, assay methods and complement sources).
Conclusions

In summary, despite the current historically low incidence of IMD in the United States, many factors remain that could increase the threat of IMD: the emergence of antibiotic-resistant strains; outbreaks and resurgences of IMD, including those caused by uncommon serogroups; suboptimal vaccine coverage; waning immunity; absence of herd immunity and, of course, the dynamic epidemiologic situation. It is necessary, while implementing current vaccination recommendations and programs, to remain vigilant for material changes in meningococcal epidemiology and to continue efforts to develop new and improved vaccines.

Acknowledgments

Medical writing support was provided by Shelley Lindley of PAREXEL. PAREXEL was funded by Sanofi Pasteur. Robert Lersch, of Sanofi Pasteur, reviewed and edited the manuscript.

References

18. Menactra® [prescribing information]. Swiftwater, PA, USA: Sanofi Pasteur Inc.
19. Menveo® [prescribing information]. Sovicille, Italy: Novartis Vaccines and Diagnostics.


